Balyasny Asset Management
YMAB

Balyasny Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Balyasny Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-43,973
Closed -$531K – 3228
2024
Q2 		$531K Buy
+43,973
New +$594K ﹤0.01% 2040
2022
Q3 		– Sell
-14,122
Closed -$214K – 3314
2022
Q2 		$214K Buy
+14,122
New +$165K ﹤0.01% 2185

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Balyasny Asset Management's YMAB Position: Q3 2024 in Review

Balyasny Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2024, closing a stake of 43,973 shares — an estimated $531K sold.

Balyasny Asset Management first reported a position in YMAB in Q2 2022 and held it in 2 quarters. The position peaked at $531K in Q2 2024. 105 funds tracked by Wall St. Rank hold YMAB as of Q3 2024.

  • Balyasny Asset Management reported no remaining Y-mAbs Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 43,973 Y-mAbs Therapeutics shares in Q3 2024, an estimated $531K.
  • Balyasny Asset Management first reported a position in Y-mAbs Therapeutics in Q2 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Y-mAbs Therapeutics position peaked at $531K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.